Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2012144208) DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-ITM2A ANTIBODY
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2012/144208 International Application No.: PCT/JP2012/002697
Publication Date: 26.10.2012 International Filing Date: 18.04.2012
IPC:
C07K 16/30 (2006.01) ,A61K 39/395 (2006.01) ,A61P 35/00 (2006.01) ,A61P 35/02 (2006.01) ,C07K 16/46 (2006.01) ,G01N 33/53 (2006.01) ,G01N 33/574 (2006.01) ,G01N 33/577 (2006.01) ,C12N 15/09 (2006.01) ,C12P 21/08 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
02
specific for leukemia
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46
Hybrid immunoglobulins
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
574
for cancer
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
577
involving monoclonal antibodies
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
P
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21
Preparation of peptides or proteins
08
Monoclonal antibodies
Applicants:
国立大学法人東京大学 The University of Tokyo [JP/JP]; 東京都文京区本郷七丁目3番1号 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo 1138654, JP (AllExceptUS)
中外製薬株式会社 CHUGAI SEIYAKU KABUSHIKI KAISHA [JP/JP]; 東京都北区浮間五丁目5番1号 5-1, Ukima 5-chome, Kita-ku, Tokyo 1158543, JP (AllExceptUS)
油谷 浩幸 ABURATANI, Hiroyuki [JP/JP]; JP (UsOnly)
石川 俊平 ISHIKAWA, Shumpei [JP/JP]; JP (UsOnly)
川合 重人 KAWAI, Shigeto [JP/JP]; JP (UsOnly)
Inventors:
油谷 浩幸 ABURATANI, Hiroyuki; JP
石川 俊平 ISHIKAWA, Shumpei; JP
川合 重人 KAWAI, Shigeto; JP
Agent:
大野 聖二 OHNO, Seiji; 東京都千代田区丸の内1丁目6番5号 丸の内北口ビル21階 大野総合法律事務所 OHNO & PARTNERS, Marunouchi Kitaguchi Building 21F, 6-5, Marunouchi 1-chome, Chiyoda-ku, Tokyo 1000005, JP
Priority Data:
2011-09248818.04.2011JP
Title (EN) DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-ITM2A ANTIBODY
(FR) DIAGNOSTIC ET TRAITEMENT DU CANCER À L'AIDE D'UN ANTICORPS ANTI-ITM2A
(JA) 抗ITM2A抗体を用いる癌の診断および治療
Abstract:
(EN) Disclosed is a monoclonal antibody capable of binding to ITM2A protein. The antibody is useful for the diagnosis, prevention and treatment of cancer such as Ewing sarcoma, T cell leukemia, T cell lymphoma, acute myelocytic leukemia, B cell tumor and multiple myeloma. Also provided are: a pharmaceutical composition, a cell proliferation inhibitor and an anti-cancer agent, each of which contains the antibody as an active ingredient; and a method for treating cancer, a method for predicting the success of a cancer therapy, and a method for determining the occurrence of cancer in a subject, each of which utilizes the antibody.
(FR) L'invention concerne un anticorps monoclonal apte à se lier à une protéine ITM2A. L'anticorps est utile pour le diagnostic, la prévention et le traitement du cancer, tel que le sarcome d'Ewing, la leucémie à lymphocytes T, le lymphome T, la leucémie myéloïde aigüe, une tumeur à lymphocytes B et un myélome multiple. L'invention concerne également : une composition pharmaceutique, un inhibiteur de prolifération cellulaire et un agent anticancéreux, chacun d'entre eux contenant l'anticorps comme principe actif ; et une méthode de traitement d'un cancer, un procédé de prédiction du succès d'une thérapie anticancéreuse, et un procédé de détermination de l'apparition d'un cancer chez un sujet, chacun d'entre eux utilisant l'anticorps.
(JA)  ITM2Aタンパク質に結合するモノクローナル抗体が開示される。この抗体は、ユーイング肉腫、T細胞性白血病、T細胞性リンパ腫、急性骨髄性白血病、B細胞腫瘍、多発性骨髄腫などの癌の診断、予防および治療に有用である。また、該抗体を有効成分として含有する医薬組成物、細胞増殖抑制剤、抗癌剤、および該抗体を用いて癌を治療する方法、癌治療の奏功性を予測する方法、および被験者における癌の存在を決定する方法も提供する。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)